Skip Navigation

Human Molecular Genetics 2005 14(Review Issue 1):R77-R84; doi:10.1093/hmg/ddi109
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Di Croce, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Croce, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Chromatin modifying activity of leukaemia associated fusion proteins

Luciano Di Croce*

ICREA and Centre de Regulació Genòmica (CRG), Passeig Maritim 37-49, 08003 Barcelona, Spain

* To whom correspondence should be addressed. Email: luciano.dicroce{at}crg.es

Received January 12, 2005; Accepted February 24, 2005

The leukaemias, which are divided into chronic and acute forms, are malignant diseases of haematopoietic cells in which the proper balance between proliferation, differentiation and apoptosis is no longer operative. Genes, such as those of mixed-lineage leukaemia, AML1 and retinoic acid receptor alpha, have been found to be aberrantly fused to different partners, which often encode transcription factors or other chromatin modifying enzymes, in numerous types of acute lymphoid and myeloid leukaemias. These chimeric fusion oncoproteins, generated by reciprocal chromosomal translocations, are responsible for chromatin alterations on target genes whose expression is critical to stem cell development or lineage specification in haematopoiesis. Alterations in the ‘histone code’ or in the DNA methylation content occur as consequence of aberrant targeting of the corresponding enzymatic activities. Here, the author will review the most recent progress in the field, focusing on how fusion proteins generated by chromosomal translocation are responsible for chromatin alterations, gene deregulation and haematopoietic differentiation block and their implication for clinical treatment.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
J. L. Barton, D. H. J. Bunka, S. E. Knowling, P. Lefevre, A. J. Warren, C. Bonifer, and P. G. Stockley
Characterization of RNA aptamers that disrupt the RUNX1-CBF{beta}/DNA complex
Nucleic Acids Res., November 1, 2009; 37(20): 6818 - 6830.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
L. Morey, C. Brenner, F. Fazi, R. Villa, A. Gutierrez, M. Buschbeck, C. Nervi, S. Minucci, F. Fuks, and L. Di Croce
MBD3, a Component of the NuRD Complex, Facilitates Chromatin Alteration and Deposition of Epigenetic Marks
Mol. Cell. Biol., October 1, 2008; 28(19): 5912 - 5923.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Villa, L. Morey, V. A. Raker, M. Buschbeck, A. Gutierrez, F. De Santis, M. Corsaro, F. Varas, D. Bossi, S. Minucci, et al.
The methyl-CpG binding protein MBD1 is required for PML-RAR{alpha} function
PNAS, January 31, 2006; 103(5): 1400 - 1405.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.